Genmab | GEN - Ebitda

Stock Price
2,097.00
Daily Change
7.00 0.33%
Monthly
4.33%
Yearly
51.08%
Q1 Forecast
1,920.90

Genmab reported DKK477M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.91B 2.31B Sep/2025
argenx SE USD 288.02M 84.53M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Bayer EUR 1.51B 1.28B Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Demant DKK 2.76B 165M Dec/2025
Exelixis USD 248.93M 28.02M Sep/2025
Fresenius Medical Care EUR 931.26M 60.26M Sep/2025
Galapagos EUR -158.71M 177.84M Mar/2025
Genmab DKK 477M 101M Sep/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
GN Store Nord DKK 521M 118M Sep/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Insmed USD -297.13M 71.11M Jun/2025
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.46B 45M Jun/2025
Novartis USD 5.88B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
UCB EUR 1.03B 334M Jun/2025